Proportion of medical insurance reimbursement for targeted drugs for lymphoma in Sichuan

Proportion of medical insurance reimbursement for targeted drugs for lymphoma in Sichuan;

1The highest reimbursement rate above 300 yuan is 85%, and the reimbursement standards of tertiary, secondary and primary hospitals are different. Self-funded drugs are not reported.

Residents' medical insurance reimbursement can be reimbursed if they are hospitalized in a hospital above the second level, and the reimbursement rate is 60% (medical insurance drugs). If the outpatient department does not provide reimbursement, it is recommended to be hospitalized for chemotherapy. The reimbursement rate for cancer is the same as that for other common diseases. For example, rural cooperatives are generally 50%, but the threshold fee and reimbursement ratio are different in each place, and some require the lowest fee. What is special about cancer is that it can start a serious illness, and part of it can be reimbursed.

Lymphoma is a malignant tumor originating from the lymphohematopoietic system, mainly characterized by painless lymphadenopathy, hepatosplenomegaly, and all tissues and organs in the whole body can be involved, accompanied by fever, night sweats, emaciation, itching and other systemic symptoms.

Tumor cells can be divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Pathologically, Hodgkin's lymphoma contains lymphocytes, eosinophils, plasma cells and specific Reed-Steinberg cells. According to pathological types, HL can be divided into nodular lymphocyte-rich type and classical type, and the latter includes lymphocyte-dominated type, nodular sclerosis type, mixed cell type and lymphocyte-depleted type. The incidence of NHL is much higher than that of HL, which is the sum of a group of independent diseases with strong heterogeneity. Pathologically, it is mainly lymphocytes, histiocytes or reticular cells with different degrees of differentiation. According to the natural course of NHL, it can be divided into three clinical types, namely, highly invasive, aggressive and inert lymphoma. According to the different sources of lymphocytes, they can be divided into B cells, T cells and NK cell lymphoma.